Evidence map›Paper›PMID 41266607›Full record

ArticleScientific reports2025

Small cell size circulating tumor cells predict the prognosis of high-risk non-muscle invasive bladder cancer patients.

Yuheng Wen, Zhihao Ming, Yichen Xiong, Hong Li, Shuai Zhu, Jian Cao, Mingji Ye, Tian Gan, Bangwen Yin, Xiangqun She and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuheng Wen *Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Zhihao Ming *Department of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yichen Xiong *Xiangya School of Stomatology, Central South University, Changsha, China.
Hong LiDepartment of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Shuai ZhuDepartment of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Jian CaoDepartment of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Mingji YeDepartment of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Tian GanDepartment of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Bangwen YinThe Second People's Hospital of Huaihua, Huaihua, Hunan, China.
Xiangqun SheThe Second People's Hospital of Huaihua, Huaihua, Hunan, China.
Yong ZengClinical Translational Research Center, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. 47537511@qq.com.
Yu XieDepartment of Urology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. xieyu420@sina.com.

Funding

National Cancer Center Clinical Research in "Climbing" Foundation of China NCC201818A55Natural Science Foundation Health Union Foundation of Hunan Province, China 2021JJ70030
6 · The paper itself

Abstract

The study aimed to explore the distribution of circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and their subtypes in non-cancer and bladder cancer individuals, focusing on their prognostic value in high-risk non-muscle invasive bladder cancer (NMIBC). Researchers analyzed 59 fresh peripheral blood samples using subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH). Samples were collected from healthy individuals (n = 18), patients with benign urinary conditions (n = 2), newly diagnosed bladder cancer patients (n = 20), and NMIBC patients after repeated transurethral resection of bladder tumor (R-TURBT) (n = 19). NMIBC patients had significantly higher total CTCs. In newly diagnosed bladder cancer patients, large CTCs constituted 58.8%. The most common karyotype was ≥ pentaploid CTCs (61.2%). In the non-cancer group, large CTCs constituted 83.0%, with ≥ pentaploid CTCs comprising 72.3% of aneuploid CTCs. For NMIBC patients after R-TURBT, those without recurrence had 16% small CTCs. Conversely, the recurrence group had 71% small CTCs, where tetraploid CTCs were predominant (40%). By performing logistic ridge repression, the ≥ pentaploid small CTC is noted as an important indicator of recurrence. The presence and proportion of small CTCs can serve as a prognostic marker in NMIBC patients following R-TURBT, potentially guiding patient management and surveillance strategies.

Indexed as

Neoplastic Cells, CirculatingUrinary Bladder NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsPrognosisBiomarkers, TumorCirculating tumor cellsNon-muscle invasive bladder cancerPrognosisSE-iFISHTURBT

Identifiers

PMID41266607
PMCPMC12635209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.